CRISPR pioneer Feng Zhang walked through his current research projects at the national meeting of the Italian Genetics Association (AGI) on September 24. CRISPR associated transposases, retrovirus-like particles repurposed as delivery vehicles, the ancestry of CRISPR systems, and more. The first issue is probably the most fascinating. It’s actually amazing to see a new activity performed by some CRISPR systems: not to protect bacteria from viruses, but to help transposons jump into specific genome sites.Continue reading
The list of the latest additions since the beginning of September is impressive. They are called CasMINI (see Molecular Cell), Cas7-11 (see Nature), OMEGAs (see Science), and come respectively from Stanford University (Stanley Qi Lab), MIT (McGovern Institute), and the Broad Institute (Zhang Lab). CasMINI is half the size of Cas9 and could be much easier to deliver. Cas7-11 is the Cas9 of RNA. OMEGAs are a new class of widespread RNA-guided enzymes, thought to be the ancestors of CRISPR.Continue reading
The Innovative Genomics Institute presents CRISPR Made Simple – the new online primer on gene editing made for kids or anyone starting from scratch.
Genotoxicity concerns: Nature Biotechnology explains how a cancer-associated phenomenon called chromothripsis could affect CRISPR therapies.
What’s unique about this book are the insights into the relationships between the main characters of the CRISPR saga. The loyal friendship linking Jennifer Doudna and George Church. The growing distrust between Doudna and Zhang. Doudna’s sorrow that she and Charpentier have drifted apart, personally as well as scientifically. The last point is indeed a melancholic note in the Nobel-ending tale. Why did their friendship fall apart?Continue reading
Doudna’s creature (Mammoth Biosciences) and Zhang’s company (Sherlock Biosciences) are developing CRISPR-based coronavirus tests similar to a home pregnancy test: portable, cheap, fast, and simple. Both will be easily adapted to detect any new emerging virus. Both received emergency use authorizations in the US in the fall of 2020 and hope to enter the market by the end of 2021. According to this piece by Walter Isaacson, competition is hot but all the intellectual property questions have been put aside for common good.
European scientists must wait for the EC to carry out targeted consultations with Member States and EU-level stakeholders. Then the Commission study on new genomic techniques will be delivered by 30 April 2021. In the meantime, the United States has decided to relax the rules for biotech crops.Continue reading
May 7th 2020 will be remembered as a good day for CRISPR. Yesterday the first CRISPR/Cas-based test received Emergency Use Authorization from the U.S. Food and Drug Administration. The Sherlock SARS-CoV2 kit works by programming a CRISPR enzyme to detect the coronavirus genetic signature, providing results in about one hour. Quickly and cheaply indeed, as the materials for one test cost about $6.Continue reading
Do you remember Sherlock? The CRISPR-based platform was heralded in Science as a new generation of low cost diagnostic tests with single-base specificity, easy to use even when oubreaks occur in remote areas. The good news is that Feng Zhang and colleagues are sharing a research protocol, applicable to purified RNA, that may inform the development of a Sherlock test for COVID-19. For more information, visit the McGovern Institute website.
Time will tell if it is going to become the preferred enzyme for genome editing or just another useful tool in the expanding CRISPR kit. But the future of CasX looks bright. It is much smaller than the nucleases that have provided a foundation for this technology. Being fewer than a thousand amino acids, it offers clear advantages for delivery in comparison with Cas9, that is over 1,300 Aa. Continue reading
60 minutes is considered “the most successful news magazine in TV history”. Don’t miss this CRISPR episode, featuring Feng Zhang, Eric Lander, Kang Zhang and Shoukhrat Mitalipov.